The Maine Medical Center Institutional Biosafety Committee (IBC) is a standing committee that has oversight of recombinant DNA (rDNA) research. All NIH funded rDNA research must be reviewed by the IBC per NIH Guidelines for Research Involving Recombinant DNA Molecules (2009). The IBC reviews and approves research to ensure safe practices, procedures, as well as handling and use of biohazardous materials for research at Maine Medical Center Research Institute.
All activities proposed to involve the use of recombinant DNA must first seek approval from the Institutional Biosafety Committee. The IBC meets at least six times per year, with dates and times announced online in advance of the meetings.
All applications for IBC review and correspondence with the IBC should be directed to the Research Compliance Office at MMCRI. For forms, application information, administration concerns, and general inquiries, please see Forms or Contact Us sections.